Many broadly neutralizing antibodies (bnAbs) against HIV-1 recognize and/or penetrate the glycan shield on native, virion-associated envelope glycoprotein (Env) spikes. The same bnAbs also bind to recombinant, soluble trimeric immunogens based on the SOSIP design. While SOSIP trimers are close structural and antigenic mimics of virion Env, the extent to which their glycan structures resemble ones on infectious viruses is undefined. Here, we compare the overall glycosylation of gp120 and gp41 subunits from BG505 (clade A) virions produced in a lymphoid cell line with those from recombinant BG505 SOSIP trimers, including CHO-derived clinical grade material. We also performed detailed site-specific analyses of gp120. Glycans relevant to key bn...
The HIV-1 envelope glycoprotein trimer is covered by an array of N-linked glycans that shield it fro...
Broadly neutralizing antibodies (bNAbs) that target the trimeric HIV-1 envelope glycoprotein spike (...
Broadly neutralizing antibodies (bNAbs) that target the trimeric HIV-1 envelope glycoprotein spike (...
Many broadly neutralizing antibodies (bnAbs) against HIV-1 recognize and/or penetrate the glycan shi...
The HIV-1 envelope glycoprotein trimer (Env) is covered by an extensive array of glycans that shield...
A highly glycosylated, trimeric envelope glycoprotein (Env) mediates HIV-1 cell entry. The high dens...
A highly glycosylated, trimeric envelope glycoprotein (Env) mediates HIV-1 cell entry. The high dens...
A highly glycosylated, trimeric envelope glycoprotein (Env) mediates HIV-1 cell entry. The high dens...
SummaryA highly glycosylated, trimeric envelope glycoprotein (Env) mediates HIV-1 cell entry. The hi...
The gp120/gp41 HIV-1 envelope glycoprotein (Env) is highly glycosylated, with up to 50% of its mass ...
Artificial glycan holes on recombinant Env-based vaccines occur when a potential N-linked glycosylat...
The gp120/gp41 HIV-1 envelope glycoprotein (Env) is highly glycosylated, with up to 50% of its mass ...
The HIV-1 envelope glycoprotein trimer is covered by an array of N-linked glycans that shield it fro...
Artificial glycan holes on recombinant Env-based vaccines occur when a potential N-linked glycosylat...
The HIV-1 envelope glycoprotein trimer is covered by an array of N-linked glycans that shield it fro...
The HIV-1 envelope glycoprotein trimer is covered by an array of N-linked glycans that shield it fro...
Broadly neutralizing antibodies (bNAbs) that target the trimeric HIV-1 envelope glycoprotein spike (...
Broadly neutralizing antibodies (bNAbs) that target the trimeric HIV-1 envelope glycoprotein spike (...
Many broadly neutralizing antibodies (bnAbs) against HIV-1 recognize and/or penetrate the glycan shi...
The HIV-1 envelope glycoprotein trimer (Env) is covered by an extensive array of glycans that shield...
A highly glycosylated, trimeric envelope glycoprotein (Env) mediates HIV-1 cell entry. The high dens...
A highly glycosylated, trimeric envelope glycoprotein (Env) mediates HIV-1 cell entry. The high dens...
A highly glycosylated, trimeric envelope glycoprotein (Env) mediates HIV-1 cell entry. The high dens...
SummaryA highly glycosylated, trimeric envelope glycoprotein (Env) mediates HIV-1 cell entry. The hi...
The gp120/gp41 HIV-1 envelope glycoprotein (Env) is highly glycosylated, with up to 50% of its mass ...
Artificial glycan holes on recombinant Env-based vaccines occur when a potential N-linked glycosylat...
The gp120/gp41 HIV-1 envelope glycoprotein (Env) is highly glycosylated, with up to 50% of its mass ...
The HIV-1 envelope glycoprotein trimer is covered by an array of N-linked glycans that shield it fro...
Artificial glycan holes on recombinant Env-based vaccines occur when a potential N-linked glycosylat...
The HIV-1 envelope glycoprotein trimer is covered by an array of N-linked glycans that shield it fro...
The HIV-1 envelope glycoprotein trimer is covered by an array of N-linked glycans that shield it fro...
Broadly neutralizing antibodies (bNAbs) that target the trimeric HIV-1 envelope glycoprotein spike (...
Broadly neutralizing antibodies (bNAbs) that target the trimeric HIV-1 envelope glycoprotein spike (...